October 25, 2016 6:15 PM ET

Healthcare Equipment and Supplies

Company Overview of Ventana Medical Systems, Inc.

Company Overview

Ventana Medical Systems Inc. develops, manufactures, and markets instrument-reagent systems that automate slide staining. Its clinical systems are used in anatomical pathology labs in analyzing human tissue to assist in diagnosing and treating cancer and infectious diseases. Ventana’s drug-discovery systems are used by pharmaceutical and biotech companies to increase the discovery of new drug targets and to evaluate the safety of new compounds. It also markets consumable products, including reagents and other accessories, and serves hospital-based anatomical pathology labs, independent reference labs, government labs, medical research centers, and resellers serving these entities. Ventana Me...

1910 East Innovation Park Drive

Tucson, AZ 85755

United States

Founded in 1985

952 Employees





Key Executives for Ventana Medical Systems, Inc.

Chief Executive Officer and Director
Age: 66
Age: 57
Founder, Chairman Emeritus, Chief Scientific Officer and Chief Medical Officer
Age: 70
Senior Vice President and General Counsel
Age: 62
Vice President of Human Resources and Vice President of Environmental Health & Safety
Age: 51
Compensation as of Fiscal Year 2016.

Ventana Medical Systems, Inc. Key Developments

Transgenomic, Inc. and Ventana Medical Systems Complete Data Sharing Agreement

Transgenomic, Inc. announced that it has signed a data sharing agreement with Ventana Medical Systems, Inc. The agreement allows Ventana to access DNA test results from an existing research agreement between Transgenomic and the University of Melbourne in Australia. As part of this research agreement, the University of Melbourne is conducting additional clinical validation studies of Transgenomic’s Multiplexed ICE COLD-PCR™ (MX-ICP) technology. The collaborative study between Transgenomic and the University of Melbourne is being conducted using DNA isolated from pre-treatment tumor biopsies from patients enrolled in clinical trials. By comparing Next Generation Sequencing (NGS) and MX-ICP, it aims to determine the prevalence and clinical significance of ultra-low frequency mutations that would otherwise go undetected by NGS or Sanger sequencing methodologies. Transgenomic’s Multiplexed ICE COLD-PCR offers major advantages over current sequencing technologies. It delivers at least a 100-fold improvement in sensitivity compared to standard methodologies, allowing detection of both known and previously unknown genetic alterations in any exon of any gene using a single assay. Its ultra-high sensitivity makes it feasible to conduct comprehensive genomic analyses using either tissue or liquid biopsies. MX-ICP is platform agnostic and works on all sequencing platforms found in labs today. It is robust, easy to use and easily implemented, requiring minimal disruption to established sequencing workflows.

Horizon Discovery Group plc and Ventana Medical Systems, Inc. Enter into Co-Development Commercialisation Agreement to Support the Development and Validation of IHC Assays

Horizon Discovery Group plc announced that it has entered into a co-development and commercialisation agreement with Ventana Medical Systems, Inc. The Agreement covers the development, manufacture and commercialisation of cell line derivative materials for use as IHC Reference Standards in cancer tissue diagnostics to support the development and validation of IHC assays. Ventana is a global leader in tissue diagnostics including immunohistochemistry (IHC), providing products used in clinical histology and drug development research laboratories worldwide. To support the development and validation of IHC assays, Ventana has partnered with Horizon as a leading provider of highly characterised Reference Standards. Under the terms of the Agreement, Ventana has the option to commission projects from Horizon, whereupon Horizon will develop the applicable cell lines and the associated derivative Reference Standard materials.  Horizon will retain primary responsibility for commercialising the Reference Standards and will serve as the primary distribution channel to end-customers in the growing tissue diagnostics market, thereby providing the Company with additional ongoing revenue streams. Ventana will hold the option to co-distribute any developed Reference Standards.

Blueprint Medicines Corporation Enters into Master Collaboration Agreement with Ventana Medical Systems, Inc

Blueprint Medicines Corporation entered into a Master Collaboration Agreement, effective March 1, 2016, and a project schedule, with Ventana Medical Systems, Inc. Pursuant to the Agreement, the company has agreed to develop and commercialize an assay as a companion diagnostic test to identify hepatocellular carcinoma (HCC) patients with aberrantly active FGFR4 signaling as indicated by FGF19 protein overexpression for use with BLU-554, one of the Company’s lead drug candidates. FGF19 is a ligand that activates FGFR4, a kinase that is aberrantly activated and is a driver of disease in a subset of patients with HCC. The parties anticipate using the company’s investigational immunohistochemistry assay to initially develop the companion diagnostic test. Under the Agreement, the company is responsible for developing, and obtaining and maintaining regulatory approvals for, the companion diagnostic test in the United States, specified countries in the European Union, any other countries that recognize the CE/in vitro diagnostic self-registration process and such other countries as the parties may mutually agree. If despite using commercially reasonable efforts the company fails, or refuses to seek, obtain or maintain regulatory approvals for, the companion diagnostic test in any country in which the company is responsible for obtaining and maintaining regulatory approvals, or in the case of certain specified supply failures or failures to commercialize the companion diagnostic test in any such country, then the parties will negotiate in good faith to select, agree upon and implement one or more alternative arrangements that are reasonably acceptable to the parties for the companion diagnostic test in such country or countries.

Similar Private Companies By Industry

Company Name Region
.decimal, Inc. United States
20/20 GeneSystems, Inc. United States
20/20 Imaging LLC United States
21st Century Scientific, Inc. United States
21X Corporation United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
NYC2012, Inc. United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Ventana Medical Systems, Inc., please visit www.ventana.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.